RecruitingNCT07399808

CDK4/6 Inhibitors in Breast Cancer Elderly Patients: an Observational Ambispective Longitudinal Multicenter Study

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Enrollment

100 participants

Start Date

Mar 21, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Old Age

Summary

Breast cancer is one of the tumors with the highest incidence and current evidence indicates a higher prevalence in elderly patients (≥70 years) with a higher mortality rate due to immunosenescence, diagnostic delay and under treatment. Elderly patients are still poorly represented in clinical trials and the main indications for the treatment of the elderly population are extrapolated from the guidelines used in studies conducted predominantly on the younger population. In particular, these guidelines do not take into account the significant variability of elderly patients, in particular their comorbidities, performance status, physiological age and frailty. The aim of this study is to improve understanding of the clinical efficacy and safety of CDK 4/6i in older women in a real-world setting compared to younger women.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is following older patients with breast cancer or other solid tumors who are receiving a class of targeted drugs called CDK4/6 inhibitors — medications that slow cancer cell division — to understand how well these treatments work and how they are tolerated in elderly patients in real-world clinical practice. **You may be eligible if...** - You are 18 or older (with focus on elderly patients) - You have a solid tumor (such as hormone-receptor positive breast cancer) and are currently receiving active treatment with a CDK4/6 inhibitor for adjuvant (post-surgery) disease **You may NOT be eligible if...** - You are unable to understand or sign an informed consent form - You are receiving CDK4/6 inhibitors for metastatic disease (not adjuvant) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Pavia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07399808

Related Trials

Genomic Services Research Program

NCT025959571 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location